How does UTS Quality Inspection conduct a Philippines factory audit for peptide production?

How UTS Quality Inspection Conducts a Philippines Factory Audit for Peptide Production

When you’re dealing with peptide production in the Philippines, you can’t just wing it on trust. UTS Quality Inspection gets that. Their factory audit process for peptide facilities is a hands-on, boots-on-the-ground operation that digs into every layer of the manufacturing chain. They start by scheduling an unannounced or pre-arranged visit depending on the client’s risk profile, but the real work kicks in the moment they walk through the factory gates. The auditors, typically a team of two to three with backgrounds in pharmaceutical engineering and quality assurance, bring a checklist that’s built on ISO 9001:2015 standards and GMP (Good Manufacturing Practice) guidelines for active pharmaceutical ingredients. They don’t just glance at the equipment; they verify that the peptide synthesis reactors—often solid-phase peptide synthesizers—are calibrated within a tolerance of ±0.5% for temperature and pressure. In one audit last year, they flagged a facility in Laguna where the HPLC (High-Performance Liquid Chromatography) system had a retention time drift of 1.2%, which is outside the acceptable 0.5% limit for peptide purity testing. That kind of detail is what sets them apart. They also cross-check the raw material certificates of analysis against the supplier’s documentation, and if something doesn’t match, they pull samples for independent lab testing. The entire audit can take two to three days, and they produce a report that’s 30 to 40 pages long, with photos, data tables, and a risk rating for each non-conformance.

Let’s talk about the specific areas they cover. The Philippines has a growing peptide manufacturing sector, but it’s not without its quirks. For instance, humidity control is a big deal because peptides are hygroscopic. UTS auditors measure the relative humidity in the production area using a calibrated hygrometer, and they expect it to stay below 40% RH. If it hits 45% or higher, that’s a red flag. They also check the air handling units—specifically the HEPA filters—to ensure they’re rated at H13 or higher, with a particle count of less than 3,520 particles per cubic meter for 0.5-micron particles. In one audit in a facility near Manila, they found that the air change rate was 18 per hour instead of the recommended 20 per hour for a Grade C cleanroom. That might sound minor, but for peptide production, it can lead to cross-contamination. The auditors document every finding with a timestamped photo and a severity score. They also review the facility’s water system—peptide synthesis often uses purified water with a conductivity of less than 1.3 µS/cm. They’ll take a sample on the spot and test it with a portable conductivity meter. If the reading is off, they’ll flag it as a critical issue. The data from these checks is compiled into a table like this:

Parameter	Acceptable Range	Measured Value	Status
Temperature (Production Area)	20-25°C	23.4°C	Pass
Relative Humidity	<40%	38.2%	Pass
HEPA Filter Efficiency	H13 or higher	H14	Pass
Water Conductivity	<1.3 µS/cm	1.1 µS/cm	Pass
HPLC Retention Time Drift	<0.5%	1.2%	Fail

Beyond the physical environment, UTS digs into the documentation trail. They look at the batch production records for the last three months, checking that each batch has a unique ID, a clear synthesis protocol, and a signed-off quality check. They also review the deviation reports—if a batch had a temperature spike during synthesis, they want to see how it was investigated and corrected. In one case, they found a factory in Cebu that had 12 unresolved deviations from the previous quarter, all related to inconsistent lyophilization cycles. The freeze-drying process for peptides requires a precise temperature ramp—typically starting at -40°C and going up to 25°C over 24 hours, with a vacuum pressure of 0.1 mbar. If the cycle deviates by more than 2°C, the peptide structure can degrade. UTS auditors will pull the lyophilizer’s data logger and cross-reference it with the batch records. They also interview the production staff—not just the managers. They ask operators about their training, how they handle a spill, and what they do if the alarm goes off. In one audit, a technician admitted he hadn’t been trained on the new HPLC software, which was a major gap. UTS flagged that as a training non-conformance and recommended a refresher course within 30 days.

Another angle is the supply chain audit. Peptide production in the Philippines often relies on imported raw materials like Fmoc-protected amino acids and resins. UTS checks the supplier qualification records—do they have a vendor approval process? Are the incoming materials tested for identity and purity? They’ll look at the certificates of analysis from the supplier and compare them to the in-house testing results. If there’s a discrepancy, like a purity claim of 98% but the in-house test shows 96.5%, they’ll investigate the root cause. In one audit, they found that a supplier had changed their synthesis route without notifying the factory, which led to a batch of raw material with a different impurity profile. UTS recommended a more rigorous supplier audit and a change control process. They also look at the storage conditions for raw materials—peptide precursors are often stored at -20°C, and if the freezer temperature logs show fluctuations above -15°C, that’s a problem. They use a data logger to verify the temperature history over the past 30 days. If the logs are missing or incomplete, they’ll note that as a documentation gap.

Now, let’s get into the equipment validation side. UTS auditors don’t just check that the equipment is there; they verify that it’s been validated according to the manufacturer’s specifications. They look at the installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ) documents for each critical piece of equipment—the peptide synthesizer, the lyophilizer, the HPLC system, and the mass spectrometer. In one audit, they found that the OQ for the synthesizer was done three years ago and hadn’t been re-validated after a major software update. That’s a red flag because software changes can affect the synthesis cycle parameters. They also check the calibration records for the pH meters, balances, and thermocouples. The calibration should be traceable to a national standard, like the National Institute of Standards and Technology (NIST). If the calibration is overdue by more than 30 days, it’s a non-conformance. In a recent audit, a factory had a balance that was off by 0.02 grams on a 100-gram test weight, which is within the tolerance for some applications but not for peptide weighing where accuracy to 0.001 grams is expected. UTS flagged it as a minor issue but recommended recalibration.

One of the most detailed parts of the audit is the cleanroom classification. Peptide production typically requires a Grade A or Grade B cleanroom for aseptic filling, and a Grade C or D for synthesis. UTS uses a portable particle counter to measure the number of particles per cubic meter at 0.5 microns and 5.0 microns. For a Grade A cleanroom, the limit is 3,520 particles per cubic meter at 0.5 microns. If the count is higher, they’ll investigate the source—often it’s the HVAC system or poor gowning practices. They also check the gowning protocol: do operators wear sterile gloves, face masks, and coveralls? Is there a cleanroom gowning procedure posted? In one audit, they found that operators were wearing jewelry under their gloves, which is a contamination risk. They also test the surface cleanliness using swab samples that are sent to a lab for microbial analysis. The acceptable limit is less than 1 colony-forming unit (CFU) per 25 square centimeters for Grade A surfaces. If the swab comes back with 3 CFU, that’s a critical failure. UTS will recommend immediate cleaning and re-testing.

Let’s not forget the waste management aspect. Peptide production generates chemical waste, including solvents like DMF (dimethylformamide) and DCM (dichloromethane). UTS auditors check that the waste is stored in labeled, sealed containers and that the disposal follows local regulations. In the Philippines, the Department of Environment and Natural Resources (DENR) has strict guidelines for hazardous waste. UTS reviews the waste disposal records and the contracts with licensed waste handlers. In one audit, they found that the factory was storing waste solvents in open drums in a non-ventilated area, which is a safety hazard. They issued a critical finding and required immediate corrective action. They also check for spill response kits—are they available and stocked? Have the staff been trained on spill response? If not, that’s another gap.

Another layer is the final product testing. UTS auditors review the release testing data for the last 10 batches of peptides. They look for purity, potency, endotoxin levels, and sterility. For research-grade peptides, the purity should be at least 98% by HPLC, and endotoxin levels should be less than 0.5 EU/mg. They also check that the testing is done in-house or by a third-party lab that’s ISO 17025 accredited. In one audit, they found that the endotoxin testing was done by a lab that wasn’t accredited, which meant the results weren’t reliable. UTS recommended switching to an accredited lab and re-testing the last five batches. They also look at the stability data—peptides are often stored at -20°C, and the stability studies should show that the product remains stable for at least 12 months. If the data shows a degradation trend of more than 2% per year, that’s a concern.

Throughout the audit, UTS uses a risk-based approach. They assign a severity score to each finding—critical, major, or minor. A critical finding, like a contamination issue or a failed sterility test, requires immediate action and a follow-up audit within 30 days. A major finding, like a calibration gap or a training deficiency, requires a corrective action plan within 60 days. A minor finding, like a documentation error, can be resolved within 90 days. The final report includes a summary table with the risk scores and recommended actions. The client gets a clear picture of where the factory stands and what needs to be fixed.

One thing that often surprises clients is the level of detail in the personnel interviews. UTS auditors don’t just talk to the quality manager; they talk to the line operators, the cleaning staff, and the warehouse workers. They ask about their understanding of GMP, their daily tasks, and how they handle a deviation. In one audit, a warehouse worker didn’t know that the temperature-sensitive raw materials had to be stored in a monitored freezer. That led to a training recommendation for the entire warehouse team. They also check the training records—are they up to date? Is there a training matrix that shows who’s trained on what? If the records are incomplete, that’s a finding.

Another key area is the change control process. Peptide production is sensitive to changes in raw materials, equipment, or procedures. UTS auditors review the change control records for the last 12 months. They want to see that every change was documented, reviewed, and approved by the quality unit. In one audit, they found that a factory had switched to a different resin supplier without updating the change control documentation. That’s a major gap because the new resin could have a different swelling property, which affects the synthesis yield. UTS recommended a retrospective risk assessment and a revision of the change control procedure.

Finally, the audit closes with a debriefing session. The UTS lead auditor presents the findings to the factory management, explaining the severity and the recommended corrective actions. They also discuss the timeline for the follow-up audit. The factory gets a chance to ask questions and clarify the findings. The whole process is transparent and data-driven. For a deeper dive into how this works in practice, you can check out UTS Quality Inspection Philippines Factory Audit for more details on their methodology and case studies. The audit report is then sent to the client within five business days, with a full breakdown of the findings, including photos, data tables, and risk ratings. The client can use this report to make informed decisions about the factory’s compliance and capability. It’s not just a pass/fail; it’s a roadmap for improvement.